Undisclosed Platform Program

About Yellowstone Biosciences

Yellowstone Biosciences is a private, preclinical-stage biotech developing novel therapies targeting common antigens in cancer. Founded in 2017 and headquartered in Oxford, UK, the company leverages pioneering academic research from Oxford University, specifically in AML, and is led by an experienced executive team with backgrounds in companies like Juno Therapeutics, Sana Biotechnology, and Immunocore. With significant backing from the FTSE 250 healthcare investor Syncona, Yellowstone is positioned to advance its platform towards identifying and validating new therapeutic targets for a range of cancers.

About Da Zen Theranostics

Da Zen Theranostics is an early-stage biotech developing a closed-loop theranostic platform for oncology, seeking to unify diagnostics and therapy into a single, personalized treatment paradigm. Operating in stealth mode with no detailed public disclosures, the company is likely in a pre-clinical or discovery research phase, building its foundational technology. Its success will hinge on validating its platform, securing substantial venture funding, and navigating the complex development path for both diagnostics and therapeutics. The company is positioned in the high-growth but competitive field of precision oncology.

Therapeutic Areas

Other Acute Myeloid Leukemia (AML) & other cancers Drugs